Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study Evaluating the Efficacy and Safety of MC-19PD1 CAR-T in Relapsed or Refractory B Cell Lymphoma

NCT03932955 is registered in ClinicalTrials.gov with Peking University as lead sponsor.

NCT NCT03932955
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03932955 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study Evaluating the Efficacy and Safety of MC-19PD1 CAR-T in Relapsed or Refractory B Cell Lymphoma
Lead sponsor
Peking University
Phase
Phase 1
Overall status
Unknown status
Start date
May 1, 2019
Completion date
May 1, 2021
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma